Advanced Insights into the Pathophysiological Mechanisms and Evolving Diagnostic Paradigms in Dilated Cardiomyopathy
Main Article Content
Abstract
Dilated cardiomyopathy represents a complex and heterogeneous myocardial disorder characterized by left ventricular or biventricular dilation and impaired systolic function in the absence of abnormal loading conditions or coronary artery disease sufficient to cause the observed systolic impairment. The clinical trajectory of this condition is marked by a progressive decline in cardiac output, ultimately culminating in congestive heart failure, malignant arrhythmias, and sudden cardiac death. Contemporary research has significantly advanced our comprehension of the intricate pathophysiological pathways underlying DCM, moving beyond a purely hemodynamic model to encompass genetic predispositions, inflammatory mediators, and metabolic dysregulations.
The identification of pathogenic variants in genes encoding for a wide array of sarcomeric, cytoskeletal, and nuclear envelope proteins has underscored the substantial heritable component of the disease, fundamentally shifting the diagnostic approach towards comprehensive family screening. This paradigm shift necessitates a multimodal assessment strategy that integrates advanced cardiac imaging, particularly echocardiography with strain analysis, and genetic testing to enable a more precise etiological classification. This article synthesizes current evidence on the molecular drivers of disease progression and discusses the critical importance of a personalized diagnostic framework aimed not only at characterizing the phenotypic expression of the disease but also at identifying specific therapeutic targets to modify its natural history and improve long-term patient outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Fatkin D, Calkins H, Elliott P, James CA, Peters S, Kovacic JC. Contemporary and future approaches to precision medicine in inherited cardiomyopathies: JACC focus seminar 3/5. J Am Coll Cardiol 2021; 77: 2551–72.
II. Henkens MTHM, Stroeks SLVM, Raafs AG, et al. Dynamic ejection fraction trajectory in patients with dilated cardiomyopathy with a truncating titin variant. Circ Heart Fail 2022; 15: e009352.
III. Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J 2018; 39: 864–73.
IV. Vissing CR, Rasmussen TB, Dybro AM, et al. Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, arrhythmias, response to treatment and sex differences. J Med Genet 2021; 58: 832–41.
V. Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019; 140: 293–302.
VI. de Frutos F, Ochoa JP, Navarro-Peñalver M, et al. Natural history of MYH7-related dilated cardiomyopathy. J Am Coll Cardiol 2022; 80: 1447–61.
VII. Verdonschot JAJ, Vanhoutte EK, Claes GRF, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020; 41: 1091–111.
VIII. Begay RL, Graw SL, Sinagra G, et al. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell-cell adhesion structures. JACC Clin Electrophysiol 2018; 4: 504–14.
IX. Lennermann D, Backs J, van den Hoogenhof MMG. New insights in RBM20 cardiomyopathy. Curr Heart Fail Rep 2020; 17: 234–46.
X. Frank D, Yusuf Rangrez A, Friedrich C, et al. Cardiac α-actin (ACTC1) gene mutation causes atrial-septal defects associated with late-onset dilated cardiomyopathy. Circ Genom Precis Med 2019; 12: e002491.
XI. Hawley MH, Almontashiri N, Biesecker LG, et al. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Hum Mutat 2020; 41: 1577–87.
XII. Hassel D, Dahme T, Erdmann J, et al. Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med 2009;15: 1281–88.
XIII. Hazebroek MR, Moors S, Dennert R, et al. Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol 2015; 66:1313–23.
XIV. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation 2022; 145: e153–639.
XV. Argirò A, Ho C, Day SM, et al. Sex-related differences in genetic cardiomyopathies. J Am Heart Assoc 2022; 11: e024947.
XVI. Crasto S, My I, Di Pasquale E. The broad spectrum of LMNA cardiac diseases: from molecular mechanisms to clinical phenotype. Front Physiol 2020; 11: 761.